User login
Key clinical point: Vedolizumab can be considered a safe and valid option for elderly patients with inflammatory bowel disease, with efficacy being unaffected by age in Crohn’s disease (CD), but slightly reduced in elderly vs. nonelderly patients with ulcerative colitis (UC).
Major finding: Nonelderly vs. elderly patients with UC showed significantly higher clinical remission at 24 months (47.3% vs. 34.3%; P < .05) and persistence (67.6% vs. 51.4%; P = .02), both of which were not significantly different between elderly and nonelderly patients with CD. Adverse events were comparable among elderly and nonelderly patients.
Study details: This was a retrospective-prospective study that included 198 elderly patients aged ≥ 65 years with UC (n = 108) or CD (n = 90) and 396 matched nonelderly patients with UC (n = 205) or CD (n = 191), all of whom received vedolizumab.
Disclosures: This study was funded by Takeda. Some authors reported receiving consulting, lecture, or speakers’ fees, or serving as advisory board members for various sources, including Takeda.
Source: Pugliese D et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56(1):95-109 (May 12). Doi: 10.1111/apt.16923
Key clinical point: Vedolizumab can be considered a safe and valid option for elderly patients with inflammatory bowel disease, with efficacy being unaffected by age in Crohn’s disease (CD), but slightly reduced in elderly vs. nonelderly patients with ulcerative colitis (UC).
Major finding: Nonelderly vs. elderly patients with UC showed significantly higher clinical remission at 24 months (47.3% vs. 34.3%; P < .05) and persistence (67.6% vs. 51.4%; P = .02), both of which were not significantly different between elderly and nonelderly patients with CD. Adverse events were comparable among elderly and nonelderly patients.
Study details: This was a retrospective-prospective study that included 198 elderly patients aged ≥ 65 years with UC (n = 108) or CD (n = 90) and 396 matched nonelderly patients with UC (n = 205) or CD (n = 191), all of whom received vedolizumab.
Disclosures: This study was funded by Takeda. Some authors reported receiving consulting, lecture, or speakers’ fees, or serving as advisory board members for various sources, including Takeda.
Source: Pugliese D et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56(1):95-109 (May 12). Doi: 10.1111/apt.16923
Key clinical point: Vedolizumab can be considered a safe and valid option for elderly patients with inflammatory bowel disease, with efficacy being unaffected by age in Crohn’s disease (CD), but slightly reduced in elderly vs. nonelderly patients with ulcerative colitis (UC).
Major finding: Nonelderly vs. elderly patients with UC showed significantly higher clinical remission at 24 months (47.3% vs. 34.3%; P < .05) and persistence (67.6% vs. 51.4%; P = .02), both of which were not significantly different between elderly and nonelderly patients with CD. Adverse events were comparable among elderly and nonelderly patients.
Study details: This was a retrospective-prospective study that included 198 elderly patients aged ≥ 65 years with UC (n = 108) or CD (n = 90) and 396 matched nonelderly patients with UC (n = 205) or CD (n = 191), all of whom received vedolizumab.
Disclosures: This study was funded by Takeda. Some authors reported receiving consulting, lecture, or speakers’ fees, or serving as advisory board members for various sources, including Takeda.
Source: Pugliese D et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56(1):95-109 (May 12). Doi: 10.1111/apt.16923